Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp

<< Previous

Bullboard Posts

Next >>

Post by HarryGlutenon Nov 06, 2021 10:02am

187 Views

Post# 34095533

MDNA tax loss selling pressure

According to Canaccord : in last 5 years, stocks on TSX down more than 15% ytd as of mid-Nov have underperformed the index by almost 4% over the month to mid-Dec and then, in the subsequent month (mid-Dec to mid-Jan) these same stocks have outperformed the index by 3.6%. $MDNA

<< Previous

Bullboard Posts

Next >>

AI companies to invest in